The impact of body mass index on dupilumab treatment outcomes in adult atopic dermatitis patients

Patruno, Cataldo; Potestio, Luca; Cecere, Daniele; Cosenza, Andrea; Brescia, Claudio; Napolitano, Maddalena

doi:10.1111/jdv.20111

Acad Dermatol Venereol

2024

DOI: 10.1111/jdv.20111

|View full text |Cite

The impact of body mass index on dupilumab treatment outcomes in adult atopic dermatitis patients

Cataldo Patruno,

Luca Potestio,

Daniele Cecere

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Efficacy and tolerance of dupilumab in patients with moderate‐to‐severe atopic dermatitis and obesity

Dupuis,

Tauber,

Mahe

et al. 2024

Acad Dermatol Venereol

View full text Add to dashboard Cite

Efficacy and tolerance of dupilumab in patients with moderate‐to‐severe atopic dermatitis and obesity

Dupuis,

Tauber,

Mahe

et al. 2024

Acad Dermatol Venereol

View full text Add to dashboard Cite

Does Body Mass Index Impact the Clinical Response to Dupilumab Therapy in Atopic Dermatitis? A Monocentric Study of 170 Patients

Nicolosi,

Barei,

Romagnuolo

et al. 2024

JCM

View full text Add to dashboard Cite

Background: Dupilumab is a monoclonal antibody used for the treatment of moderate/severe atopic dermatitis (AD). In recent years, several studies have confirmed the positive association between AD and overweight/obesity, and a report demonstrated the effect of weight reduction on the improvement of AD symptoms. Methods: The weight of 170 patients under treatment with dupilumab was recorded at baseline and after 48 weeks (T48). Clinical monitoring was mainly conducted using the Eczema Area and Severity Index (EASI). The study aimed to assess a possible correlation between the clinical outcome of dupilumab therapy and BMI. Results: Although not statistically significant, patients with a BMI < 25 have a higher EASI percentage improvement than patients with a BMI ≥ 25 at any time point, and the percentage of overweight and obese patients that does not reach EASI-75 at T48 is higher compared to normal-weight patients (13.5% vs. 5.9%). Despite this, in the multivariate regression analysis, no baseline characteristic, including BMI, appears to increase the risk of not reaching EASI-75. In addition, the results show no differences in BMI between baseline and T48 in any age/sex group. Conclusions: The results suggest that overweight and obese patients have a lower response to dupilumab when considering the EASI score, but this difference does not appear to be clinically significant. Furthermore, dupilumab treatment does not seem to impact weight.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The impact of body mass index on dupilumab treatment outcomes in adult atopic dermatitis patients

Cited by 2 publications

References 8 publications

Efficacy and tolerance of dupilumab in patients with moderate‐to‐severe atopic dermatitis and obesity

Efficacy and tolerance of dupilumab in patients with moderate‐to‐severe atopic dermatitis and obesity

Does Body Mass Index Impact the Clinical Response to Dupilumab Therapy in Atopic Dermatitis? A Monocentric Study of 170 Patients

Contact Info

Product

Resources

About